Jaguar Health submits abstract for breast cancer diarrhea study using patient-reported outcomes.

Jaguar Health has submitted an abstract for a study assessing diarrhea caused by cancer therapies in breast cancer patients from the OnTarget Phase 3 trial. The research, involving 142 patients, including 75 with breast cancer, utilizes patient-reported outcomes via digital applications. This study may be the first to document gastrointestinal symptoms directly from patients, aiming to enhance understanding and management of cancer therapy-related diarrhea (CTD).

October 08, 2024
6 Articles